Health · Full coverage
FDA Approves Breakthrough Oral Drug Drexonersib for Metastatic Pancreatic Cancer
How 2 Israeli newsrooms covered this story — translated into English and compared side by side.
50% center
Center 1Right 1
First reported by Now 14 · 2 hours ago
What happened
The FDA approved Drexonersib, a once-daily oral drug for metastatic pancreatic cancer, after a phase 3 trial showed it doubled median survival to 13.2 months. The drug will soon be available in Israel but may be costly.
- 01FDA approved Drexonersib for metastatic pancreatic cancer six months early.
- 02The drug is taken orally once daily at 300 mg dosage.
- 03Phase 3 trial included 500 previously treated patients.
- 04Median survival with Drexonersib was 13.2 months versus 6.7 months with chemotherapy.
- 05Drexonersib will soon be imported to Israel with high expected costs.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 2 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
Related stories
FDA Approves Revtorpyk to Cut Advanced Breast Cancer Progression Risk by 76%Jul 15, 2026Ichilov Launches World-First Clinical Trial for Innovative Pancreatic Cancer TreatmentJul 30, 2026FDA Approves New Oral Drug Iberdomide for Multiple Myeloma PatientsAug 17, 2026Cancer Vaccine Shows Promise, Leaving One Patient Disease-Free for More Than Six YearsJun 11, 2026New Targeted Therapies Revolutionize Breast Cancer Treatment and Survival in IsraelJul 5, 2026FDA Approval Opens New Treatment Path for Children with Type 1 DiabetesJun 25, 2026
